Weiss Asset Management LP Makes New Investment in Hims & Hers Health, Inc. $HIMS

Weiss Asset Management LP purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 28,680 shares of the company’s stock, valued at approximately $595,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Binnacle Investments Inc acquired a new position in shares of Hims & Hers Health in the third quarter worth approximately $28,000. Flagship Harbor Advisors LLC acquired a new stake in Hims & Hers Health during the 4th quarter valued at approximately $28,000. Bogart Wealth LLC raised its holdings in Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in Hims & Hers Health during the 1st quarter worth approximately $30,000. Finally, Greenline Wealth Management LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Activity

In related news, CFO Oluyemi Okupe sold 18,197 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $34.03, for a total value of $619,243.91. Following the completion of the sale, the chief financial officer directly owned 284,321 shares of the company’s stock, valued at $9,675,443.63. The trade was a 6.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $441,850.50. Following the completion of the transaction, the chief operating officer owned 432,124 shares in the company, valued at approximately $13,611,906. The trade was a 3.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 83,126 shares of company stock valued at $2,711,339. Corporate insiders own 11.76% of the company’s stock.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $30.23 on Tuesday. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43. The company has a fifty day moving average of $30.91 and a 200-day moving average of $26.25. The firm has a market capitalization of $7.00 billion, a P/E ratio of -335.84, a P/E/G ratio of 79.05 and a beta of 2.35.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm’s revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.20 earnings per share. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.03 EPS for the current year.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of analyst reports. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Barclays boosted their target price on shares of Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a report on Wednesday, June 17th. Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Citigroup increased their price target on Hims & Hers Health from $28.00 to $35.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $25.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, May 5th. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $31.43.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.